STONY BROOK, N.Y. – August 8, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced consolidated financial results for its third fiscal quarter ended June 30, 2024. The Company’s Form 10-Q can be viewed at https://investors.adnas.com/sec-filings/. Third Quarter Operational Highlights [...]
STONY BROOK, N.Y. – August 7, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its third quarter fiscal 2024 financial results after market close on Thursday, August 8, 2024. In conjunction with this announcement, Applied [...]
Applied DNA Sciences has signed a five-year licensing and commercial-based agreement with vertically integrated textile manufacturer Indus Group for the DNA authentication firm's CertainT platform.
By Shemona Safaya Biotechnology company Applied DNA Sciences has signed a five-year licensing and commercial-based agreement with apparel-textile manufacturer and sourcing firm Indus Group for CertainT's first large-scale deployment as a cotton traceability platform. Under the terms of the agreement Applied DNA will supply Indus with its CertainT platform for non-home, cotton-based products (apparel, [...]
STONY BROOK, N.Y. – July 29, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, will present a poster at the 4th Annual mRNA-based Therapeutics Summit taking place July 29 – 31, 2024, in Boston. The poster presents the Company’s Linea™ IVT platform – a combination [...]
STONY BROOK, N.Y. July 25, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced the signing of a five-year license and commercialization agreement for its CertainT® traceability platform (the “Agreement”) with Indus Group (“Indus”) a multinational apparel/textile manufacturing and sourcing company [...]
STONY BROOK, N.Y., July 18, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that the U.S. Defense Logistics Agency (DLA) exercised the first one-year option period of a three-year base contract with two one-year option periods entered into in May 2021. The contract supports DLA’s counterfeit [...]
STONY BROOK, N.Y., and JUPITER, FL – June 20, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, and Alphazyme LLC (Alphazyme), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of specialty enzymes used in the life sciences sector, announced the successful conclusion of [...]
STONY BROOK, N.Y., June 18, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a global leader in PCR-based DNA technologies, today announced that its molecular diagnostics subsidiary, Applied DNA Clinical Labs, LLC (ADCL), will utilize the GenXys Health Care Systems (GenXys) suite of clinical decision support software for interpretation and reporting [...]